Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 208

1.

Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline.

Crugnola M, Castagnetti F, Breccia M, Ferrero D, Trawinska MM, Abruzzese E, Annunziata M, Stagno F, Tiribelli M, Binotto G, Bonifacio M, Fava C, Iurlo A, Bucelli C, Mansueto G, Gozzini A, Falzetti F, Montefusco E, Crisà E, Gugliotta G, Russo S, Cedrone M, RussoRossi A, Pregno P, Isidori A, Mauro E, Atelda R, Giglio G, Celesti F, Sorà F, Storti S, D'Addosio A, Galimberti S, Orlandi E, Calistri E, Bocchia M, Cavazzini F, Rege Cambrin G, Orofino N, Luciano L, Sgherza N, Rosti G, Latagliata R, Capodanno I.

Ann Hematol. 2019 Aug 7. doi: 10.1007/s00277-019-03767-y. [Epub ahead of print]

PMID:
31392461
2.

REAL-WORD EXPERIENCE WITH DECITABINE AS A FIRST-LINE TREATMENT IN 306 ELDERLY ACUTE MYELOID LEUKAEMIA PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY.

Bocchia M, Candoni A, Borlenghi E, Defina M, Filì C, Cattaneo C, Sammartano V, Fanin R, Sciumè M, Sicuranza A, Imbergamo S, Riva M, Fracchiolla N, Latagliata R, Caizzi E, Mazziotta F, Alunni G, Di Bona E, Crugnola M, Rossi M, Consoli U, Fontanelli G, Greco G, Nadali G, Rotondo F, Todisco E, Bigazzi C, Capochiani E, Molteni A, Bernardi M, Fumagalli M, Rondoni M, Scappini B, Ermacora A, Simonetti F, Gottardi M, Lambertenghi Deliliers D, Michieli MG, Basilico C, Galeone C, Pelucchi C, Rossi G.

Hematol Oncol. 2019 Aug 5. doi: 10.1002/hon.2663. [Epub ahead of print]

PMID:
31385337
3.

Digital droplet PCR at the time of TKI discontinuation in chronic-phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome.

Colafigli G, Scalzulli E, Porrazzo M, Diverio D, Loglisci MG, Latagliata R, Guarini A, Foà R, Breccia M.

Hematol Oncol. 2019 Jul 19. doi: 10.1002/hon.2650. [Epub ahead of print] No abstract available.

PMID:
31321792
4.

Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis.

Breccia M, Luciano L, Pugliese N, Rossi E, Tiribelli M, Scalzulli E, Bonifacio M, Martino B, Latagliata R, Benevolo G, Caocci G, Binotto G, Martinelli V, Cavo M, Pane F, De Stefano V, Foà R, Palandri F.

Ann Hematol. 2019 Aug;98(8):1933-1936. doi: 10.1007/s00277-019-03727-6. Epub 2019 Jun 14.

PMID:
31201513
5.

Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice.

Scalzulli E, Molica M, Alunni Fegatelli D, Colafigli G, Rizzo L, Mancini M, Efficace F, Latagliata R, Foà R, Breccia M.

Ann Hematol. 2019 Aug;98(8):1919-1925. doi: 10.1007/s00277-019-03724-9. Epub 2019 Jun 5.

PMID:
31168652
6.

Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life.

Molica M, Colafigli G, Scalzulli E, Alunni Fegatelli D, Chiatamone Ranieri S, Rizzo L, Diverio D, Efficace F, Latagliata R, Foà R, Breccia M.

Ann Hematol. 2019 Aug;98(8):1891-1904. doi: 10.1007/s00277-019-03706-x. Epub 2019 May 11.

PMID:
31079264
7.

Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.

Andriani A, Elli E, Trapè G, Villivà N, Fianchi L, Di Veroli A, Niscola P, Centra A, Anaclerico B, Montanaro G, Martini V, Aroldi A, Carmosino I, Voso MT, Breccia M, Montanaro M, Foà R, Latagliata R.

Hematol Oncol. 2019 May 3. doi: 10.1002/hon.2635. [Epub ahead of print]

PMID:
31050810
8.

Management and outcome of 11 pregnancies in women with polycythemia vera.

Elli EM, Diral E, Gambacorti-Passerini C, Calori R, Carmosino I, Breccia M, Latagliata R, Di Veroli A.

Leuk Res. 2019 Jun;81:25-26. doi: 10.1016/j.leukres.2019.04.003. Epub 2019 Apr 8. No abstract available.

PMID:
30986630
9.

Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.

Palandri F, Palumbo GA, Abruzzese E, Iurlo A, Polverelli N, Elli E, Bonifacio M, Bergamaschi M, Martino B, Tiribelli M, Benevolo G, Tieghi A, Sgherza N, Isidori A, Binotto G, Crugnola M, Heidel F, Cavazzini F, Bosi C, Auteri G, Cattaneo D, Foà R, Lemoli RM, Cuneo A, Krampera M, Bartoletti D, Cavo M, Vianelli N, Breccia M, Latagliata R.

Hematol Oncol. 2019 Apr 15. doi: 10.1002/hon.2619. [Epub ahead of print]

PMID:
30985017
10.

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.

Fava C, Rege-Cambrin G, Dogliotti I, Cerrano M, Berchialla P, Dragani M, Rosti G, Castagnetti F, Gugliotta G, Martino B, Gambacorti-Passerini C, Abruzzese E, Elena C, Pregno P, Gozzini A, Capodanno I, Bergamaschi M, Crugnola M, Bocchia M, Galimberti S, Rapezzi D, Iurlo A, Cattaneo D, Latagliata R, Breccia M, Cedrone M, Santoro M, Annunziata M, Levato L, Stagno F, Cavazzini F, Sgherza N, Giai V, Luciano L, Russo S, Musto P, Caocci G, Sorà F, Iuliano F, Lunghi F, Specchia G, Pane F, Ferrero D, Baccarani M, Saglio G.

Haematologica. 2019 Aug;104(8):1589-1596. doi: 10.3324/haematol.2018.205054. Epub 2019 Feb 28.

11.

Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?

Di Veroli A, Campagna A, De Muro M, Maurillo L, Trawinska MM, LeonettiCrescenzi S, Petriccione L, Romano A, D'Addosio A, Cenfra A, Montanaro M, Felici S, Andriani A, Carmosino I, Niscola P, Montefusco E, Breccia M, Latagliata R.

Leuk Res. 2019 Jan;76:65-69. doi: 10.1016/j.leukres.2018.11.012. Epub 2018 Dec 4.

PMID:
30578958
12.

Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study.

Palandri F, Palumbo GA, Iurlo A, Polverelli N, Benevolo G, Breccia M, Abruzzese E, Tiribelli M, Bonifacio M, Tieghi A, Isidori A, Martino B, Sgherza N, D'Adda M, Bergamaschi M, Crugnola M, Cavazzini F, Bosi C, Binotto G, Auteri G, Latagliata R, Ibatici A, Scaffidi L, Penna D, Cattaneo D, Soci F, Trawinska M, Russo D, Cuneo A, Semenzato G, Di Raimondo F, Aversa F, Lemoli RM, Heidel F, Reggiani MLB, Bartoletti D, Cavo M, Catani L, Vianelli N.

Semin Hematol. 2018 Oct;55(4):248-255. doi: 10.1053/j.seminhematol.2018.05.013. Epub 2018 Jun 5.

PMID:
30502854
13.

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib.

Breccia M, Bartoletti D, Bonifacio M, Palumbo GA, Polverelli N, Abruzzese E, Bergamaschi M, Tieghi A, Tiribelli M, Iurlo A, Cavazzini F, Sgherza N, Binotto G, Isidori A, D'Adda M, Crugnola M, Bosi C, Heidel F, Molica M, Scaffidi L, Cattaneo D, Latagliata R, Auteri G, Lemoli RM, Fanin R, Russo D, Aversa F, Cuneo A, Semenzato G, Catani L, Cavo M, Vianelli N, Foà R, Palandri F.

Ann Hematol. 2019 Apr;98(4):889-896. doi: 10.1007/s00277-018-3569-1. Epub 2018 Dec 4.

PMID:
30515542
14.

Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations.

Girmenia C, Candoni A, Delia M, Latagliata R, Molteni A, Oliva EN, Palumbo GA, Poloni A, Salutari P, Santini V, Voso MT, Musto P.

Blood Rev. 2019 Mar;34:16-25. doi: 10.1016/j.blre.2018.10.002. Epub 2018 Oct 28. Review.

PMID:
30448050
15.

Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients.

Palandri F, Palumbo GA, Bonifacio M, Breccia M, Latagliata R, Martino B, Polverelli N, Abruzzese E, Tiribelli M, Nicolosi M, Bergamaschi M, Tieghi A, Iurlo A, Sgherza N, Cavazzini F, Isidori A, Binotto G, Ibatici A, Crugnola M, Heidel F, Bosi C, Bartoletti D, Auteri G, Catani L, Cuneo A, Aversa F, Semenzato G, Cavo M, Vianelli N, Benevolo G.

Leuk Res. 2018 Nov;74:86-88. doi: 10.1016/j.leukres.2018.10.001. Epub 2018 Oct 5. No abstract available.

PMID:
30321784
16.

The IPSS-R has prognostic impact in untreated patients with MDS del(5q).

Kaivers J, Lauseker M, Hildebrandt B, Fenaux P, Pfeilstöcker M, Valent P, Platzbecker U, Latagliata R, Oliva EN, Xicoy B, Götze K, Ganster C, Haase D, Bug G, Kündgen A, Gattermann N, Haas R, Germing U.

Leuk Res. 2018 Sep;72:27-33. doi: 10.1016/j.leukres.2018.07.019. Epub 2018 Jul 23.

PMID:
30075323
17.

Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes.

Gurnari C, Latagliata R, Buccisano F, Piciocchi A, Fenu S, Mancini S, Fianchi L, Criscuolo M, Sarlo C, Romano A, Falconi G, Niscola P, Di Veroli A, Breccia M, Piccioni A, Aloe-Spiriti MA, Lo-Coco F, Voso MT; GROM-L (Gruppo Romano-Laziale MDS); GROM-L (Gruppo Romano-Laziale MDS).

Leuk Res. 2018 Aug;71:89-91. doi: 10.1016/j.leukres.2018.07.002. Epub 2018 Jul 10. No abstract available.

PMID:
30029156
18.

Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.

Palandri F, Catani L, Bonifacio M, Benevolo G, Heidel F, Palumbo GA, Crugnola M, Abruzzese E, Bartoletti D, Polverelli N, Bergamaschi M, Tiribelli M, Iurlo A, Breccia M, Cavazzini F, Tieghi A, Binotto G, Isidori A, Martino B, D'Adda M, Bosi C, Sabattini E, Vitolo U, Aversa F, Ibatici A, Lemoli RM, Sgherza N, Cuneo A, Martinelli G, Semenzato G, Cavo M, Vianelli N, Sapienza MR, Latagliata R.

Br J Haematol. 2018 Oct;183(1):35-46. doi: 10.1111/bjh.15497. Epub 2018 Jul 16.

PMID:
30010187
19.

Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.

Cicconi L, Breccia M, Franceschini L, Latagliata R, Molica M, Divona M, Diverio D, Rizzo M, Ottone T, Iaccarino L, Alfonso V, Foa R, Voso MT, Lo-Coco F.

Ann Hematol. 2018 Oct;97(10):1797-1802. doi: 10.1007/s00277-018-3400-z. Epub 2018 Jun 27.

PMID:
29951912
20.

Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?

Latagliata R, Breccia M, Carmosino I, Cesini L, De Benedittis D, Mohamed S, Vozella F, Molica M, Campanelli M, De Luca ML, Colafigli G, Quattrocchi L, Loglisci MG, Massaro F, Canichella M, Diverio D, Mancini M, Alimena G, Foà R.

Eur J Haematol. 2018 Jun 13. doi: 10.1111/ejh.13110. [Epub ahead of print]

PMID:
29896890
21.

Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events.

Molica M, Scalzulli E, Colafigli G, Fegatelli DA, Massaro F, Latagliata R, Foà R, Breccia M.

Ann Hematol. 2018 Oct;97(10):1803-1808. doi: 10.1007/s00277-018-3375-9. Epub 2018 May 27.

PMID:
29806063
22.

Iron toxicity - Its effect on the bone marrow.

Isidori A, Borin L, Elli E, Latagliata R, Martino B, Palumbo G, Pilo F, Loscocco F, Visani G, Cianciulli P.

Blood Rev. 2018 Nov;32(6):473-479. doi: 10.1016/j.blre.2018.04.004. Epub 2018 Apr 13. Review.

PMID:
29699840
23.

Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up.

Di Veroli A, Buccisano F, Andriani A, Montanaro M, Latagliata R, Santoro C, Breccia M, Spirito F, Cedrone M, Anaclerico B, Leonetti Crescenzi S, Porrini R, De Muro M, Avvisati G, Tafuri A, Cimino G, Spadea A.

Leuk Res. 2018 Jun;69:18-23. doi: 10.1016/j.leukres.2018.03.016. Epub 2018 Mar 31. No abstract available.

PMID:
29625320
24.

Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.

Polverelli N, Palumbo GA, Binotto G, Abruzzese E, Benevolo G, Bergamaschi M, Tieghi A, Bonifacio M, Breccia M, Catani L, Tiribelli M, D'Adda M, Sgherza N, Isidori A, Cavazzini F, Martino B, Latagliata R, Crugnola M, Heidel F, Bosi C, Ibatici A, Soci F, Penna D, Scaffidi L, Aversa F, Lemoli RM, Vitolo U, Cuneo A, Russo D, Cavo M, Vianelli N, Palandri F.

Hematol Oncol. 2018 Apr 6. doi: 10.1002/hon.2509. [Epub ahead of print]

PMID:
29624703
25.

Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib.

Breccia M, Molica M, Colafigli G, Massaro F, Quattrocchi L, Latagliata R, Mancini M, Diverio D, Guarini A, Alimena G, Foà R.

Oncotarget. 2017 Dec 26;9(7):7534-7540. doi: 10.18632/oncotarget.23691. eCollection 2018 Jan 26.

26.

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.

Palandri F, Palumbo GA, Bonifacio M, Tiribelli M, Benevolo G, Martino B, Abruzzese E, D'Adda M, Polverelli N, Bergamaschi M, Tieghi A, Cavazzini F, Ibatici A, Crugnola M, Bosi C, Latagliata R, Di Veroli A, Scaffidi L, de Marchi F, Cerqui E, Anaclerico B, De Matteis G, Spinsanti M, Sabattini E, Catani L, Aversa F, Di Raimondo F, Vitolo U, Lemoli RM, Fanin R, Merli F, Russo D, Cuneo A, Bacchi Reggiani ML, Cavo M, Vianelli N, Breccia M.

Oncotarget. 2017 Jun 27;8(45):79073-79086. doi: 10.18632/oncotarget.18674. eCollection 2017 Oct 3.

27.

Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.

Iurlo A, Galimberti S, Abruzzese E, Annunziata M, Bonifacio M, Latagliata R, Pregno P, Ferrero D, Sorà F, Orlandi EM, Fava C, Cattaneo D, Bucelli C, Binotto G, Pungolino E, Tiribelli M, Gozzini A, Gugliotta G, Castagnetti F, Stagno F, Rege-Cambrin G, Martino B, Luciano L, Breccia M, Sica S, Bocchia M, Pane F, Saglio G, Rosti G, Specchia G, Cortelezzi A, Baccarani M.

Ann Hematol. 2018 Jan;97(1):95-100. doi: 10.1007/s00277-017-3144-1. Epub 2017 Oct 2.

PMID:
28971265
28.

Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life.

Breccia M, Colafigli G, Molica M, Scalzulli E, Diverio D, Latagliata R, Guarini A, Foà R.

Am J Hematol. 2017 Dec;92(12):E668-E670. doi: 10.1002/ajh.24916. Epub 2017 Oct 19. No abstract available.

29.

The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials.

Molica M, Canichella M, Alunni Fegatelli D, Colafigli G, Massaro F, Latagliata R, Foà R, Breccia M.

Am J Hematol. 2017 Dec;92(12):E661-E664. doi: 10.1002/ajh.24913. Epub 2017 Oct 19. No abstract available.

30.

A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry.

Mayer F, Faglioni L, Agabiti N, Fenu S, Buccisano F, Latagliata R, Ricci R, Spiriti MAA, Tatarelli C, Breccia M, Cimino G, Fianchi L, Criscuolo M, Gumenyuk S, Mancini S, Maurillo L, Nobile C, Niscola P, Piccioni AL, Tafuri A, Trapè G, Andriani A, De Fabritiis P, Voso MT, Davoli M, Zini G.

Mediterr J Hematol Infect Dis. 2017 Jul 1;9(1):e2017046. doi: 10.4084/MJHID.2017.046. eCollection 2017.

31.

Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors.

Molica M, Canichella M, Colafigli G, Latagliata R, Diverio D, Alimena G, Foà R, Breccia M.

Br J Haematol. 2018 Aug;182(3):427-429. doi: 10.1111/bjh.14783. Epub 2017 Jul 5. No abstract available.

PMID:
28677850
32.

ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems.

Buckstein R, Balleari E, Wells R, Santini V, Sanna A, Salvetti C, Crisà E, Allione B, Danise P, Finelli C, Clavio M, Poloni A, Salvi F, Cilloni D, Oliva EN, Musto P, Houston B, Zhu N, Geddes M, Leitch H, Leber B, Sabloff M, Nevill TJ, Yee KW, Storring JM, Francis J, Maurillo L, Latagliata R, Spiriti MAA, Andriani A, Piccioni AL, Fianchi L, Fenu S, Gumenyuk S, Buccisano F.

Am J Hematol. 2017 Oct;92(10):1037-1046. doi: 10.1002/ajh.24842. Epub 2017 Jul 29.

33.

High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia.

Latagliata R, Montanaro M, Cedrone M, Di Veroli A, Spirito F, Santoro C, Leonetti Crescenzi S, Porrini R, Di Giandomenico J, Villivà N, Spadea A, Rago A, De Gregoris C, Romano A, Anaclerico B, De Muro M, Felici S, Breccia M, Montefusco E, Bagnato A, Cimino G, Majolino I, Mazzucconi MG, Alimena G, Andriani A; Gruppo Laziale, SMPC Ph1.

Thromb Res. 2017 Aug;156:168-171. doi: 10.1016/j.thromres.2017.06.023. Epub 2017 Jun 21.

PMID:
28662484
34.

Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia.

Santoro C, Sperduti I, Latagliata R, Baldacci E, Anaclerico B, Avvisati G, Breccia M, Buccisano F, Cedrone M, Cimino G, De Gregoris C, De Muro M, Di Veroli A, Leonetti Crescenzi S, Montanaro M, Montefusco E, Porrini R, Rago A, Spadea A, Spirito F, Villivà N, Andriani A, Alimena G, Mazzucconi MG.

Cancer Med. 2017 Jun;6(6):1233-1239. doi: 10.1002/cam4.1081. Epub 2017 May 23.

35.

Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.

Palandri F, Tiribelli M, Benevolo G, Tieghi A, Cavazzini F, Breccia M, Bergamaschi M, Sgherza N, Polverelli N, Crugnola M, Isidori A, Binotto G, Heidel FH, Buccisano F, Martino B, Latagliata R, Spinsanti M, Kallenberg L, Palumbo GA, Abruzzese E, Scaffidi L, Cuneo A, Cavo M, Vianelli N, Bonifacio M.

Hematol Oncol. 2018 Feb;36(1):285-290. doi: 10.1002/hon.2429. Epub 2017 May 17.

PMID:
28512865
36.

Comparison of JAK2V617F -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology.

Latagliata R, Polverelli N, Tieghi A, Palumbo GA, Breccia M, Sabattini E, Villari L, Riminucci M, Valli R, Catani L, Alimena G, Ottaviani E, Fama A, Martinelli G, Perricone M, Spinsanti M, Cavo M, Vianelli N, Palandri F.

Hematol Oncol. 2018 Feb;36(1):269-275. doi: 10.1002/hon.2430. Epub 2017 May 16.

PMID:
28509339
37.

Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib.

Molica M, Breccia M, Colafigli G, Massaro F, Quattrocchi L, Mancini M, Diverio D, Latagliata R, Foà R.

Br J Haematol. 2018 Apr;181(2):275-278. doi: 10.1111/bjh.14560. Epub 2017 Feb 17. No abstract available.

PMID:
28211562
38.

Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome.

Sora F, Iurlo A, Sica S, Latagliata R, Annunziata M, Galimberti S, Castagnetti F, Pregno P, Sgherza N, Celesti F, Bocchia M, Gozzini A, Fava C, Cattaneo D, Crugnola M, Montefusco E, Mauro E, Capodanno I, Breccia M.

Br J Haematol. 2018 Apr;181(2):267-270. doi: 10.1111/bjh.14553. Epub 2017 Feb 7. No abstract available.

PMID:
28169426
39.

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.

Oliva EN, Alati C, Santini V, Poloni A, Molteni A, Niscola P, Salvi F, Sanpaolo G, Balleari E, Germing U, Fenaux P, Stamatoullas A, Palumbo GA, Salutari P, Impera S, Avanzini P, Cortelezzi A, Liberati AM, Carluccio P, Buccisano F, Voso MT, Mancini S, Kulasekararaj A, Morabito F, Bocchia M, Cufari P, Spiriti MA, Santacaterina I, D'Errigo MG, Bova I, Zini G, Latagliata R.

Lancet Haematol. 2017 Mar;4(3):e127-e136. doi: 10.1016/S2352-3026(17)30012-1. Epub 2017 Feb 3.

PMID:
28162984
40.

Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.

Breccia M, Andriani A, Montanaro M, Abruzzese E, Buccisano F, Cedrone M, Centra A, Villivà N, Celesti F, Trawinska MM, Massaro F, Di Veroli A, Anaclerico B, Colafigli G, Molica M, Spadea A, Petriccione L, Cimino G, Latagliata R.

Ann Hematol. 2017 Mar;96(3):387-391. doi: 10.1007/s00277-016-2884-7. Epub 2016 Nov 26.

PMID:
27889820
41.

Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients.

Polverelli N, Breccia M, Benevolo G, Martino B, Tieghi A, Latagliata R, Sabattini E, Riminucci M, Godio L, Catani L, Nicolosi M, Perricone M, Sollazzo D, Colafigli G, Campana A, Merli F, Vitolo U, Alimena G, Martinelli G, Lewis RE, Vianelli N, Cavo M, Palandri F.

Am J Hematol. 2017 Jan;92(1):37-41. doi: 10.1002/ajh.24572. Epub 2016 Nov 12.

42.

Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia.

Latagliata R, Stagno F, Annunziata M, Abruzzese E, Iurlo A, Guarini A, Fava C, Gozzini A, Bonifacio M, Sorà F, Leonetti Crescenzi S, Bocchia M, Crugnola M, Castagnetti F, Capodanno I, Galimberti S, Feo C, Porrini R, Pregno P, Rizzo M, Antolino A, Mauro E, Sgherza N, Luciano L, Tiribelli M, Russo Rossi A, Trawinska M, Vigneri P, Breccia M, Rosti G, Alimena G.

Neoplasia. 2016 Sep;18(9):536-40. doi: 10.1016/j.neo.2016.07.005.

43.

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome.

Iurlo A, Nobili A, Latagliata R, Bucelli C, Castagnetti F, Breccia M, Abruzzese E, Cattaneo D, Fava C, Ferrero D, Gozzini A, Bonifacio M, Tiribelli M, Pregno P, Stagno F, Vigneri P, Annunziata M, Cavazzini F, Binotto G, Mansueto G, Russo S, Falzetti F, Montefusco E, Gugliotta G, Storti S, D'Addosio AM, Scaffidi L, Cortesi L, Cedrone M, Rossi AR, Avanzini P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Rege-Cambrin G, Sica S, Luciano L, Galimberti S, Orlandi EM, Bocchia M, Tettamanti M, Alimena G, Saglio G, Rosti G, Mannucci PM, Cortelezzi A.

Oncotarget. 2016 Nov 29;7(48):80083-80090. doi: 10.18632/oncotarget.11657.

44.

Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia.

Chisini M, Stefanizzi C, Ceglie T, Raponi S, Vozella F, Colafigli G, Salaroli A, D'Angiò M, Mancini M, Diverio D, Breccia M, Mancini F, Minotti C, Trisolini S, Capria S, Testi AM, Guarini A, Latagliata R, De Propris MS, Foà R.

Hematol Oncol. 2017 Dec;35(4):804-809. doi: 10.1002/hon.2331. Epub 2016 Jul 12.

PMID:
27400753
45.

The risk of infections in patients with myelodysplastic syndromes in 2016.

Caira M, Latagliata R, Girmenia C.

Expert Rev Hematol. 2016 Jun;9(6):607-14. doi: 10.1080/17474086.2016.1181540. Epub 2016 May 5. Review.

PMID:
27100058
46.

Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study.

Buccisano F, Piccioni AL, Nobile C, Criscuolo M, Niscola P, Tatarelli C, Fianchi L, Villivà N, Neri B, Carmosino I, Gumenyuk S, Mancini S, Voso MT, Maurillo L, Breccia M, Zini G, Venditti A, Fenu S, Spiriti MA, Latagliata R; GROM (Gruppo Romano Mielodisplasie).

Ann Hematol. 2016 Jun;95(7):1059-65. doi: 10.1007/s00277-016-2667-1. Epub 2016 Apr 19.

PMID:
27091349
47.

JAK2(V617F) allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy.

Barosi G, Klersy C, Villani L, Bonetti E, Catarsi P, Poletto V, Campanelli R, Impera S, Latagliata R, Viarengo G, Carolei A, Massa M, Musso M, Crescimanno A, Gale RP, Rosti V.

Leukemia. 2016 Aug;30(8):1772-5. doi: 10.1038/leu.2016.45. Epub 2016 Feb 29. No abstract available.

PMID:
26975727
48.

Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients.

Andriani A, Latagliata R, Anaclerico B, Spadea A, Rago A, Di Veroli A, Spirito F, Porrini R, De Muro M, Crescenzi Leonetti S, Villivà N, De Gregoris C, Montefusco E, Polverelli N, Santoro C, Breccia M, Cimino G, Majolino I, Mazzucconi MG, Vianelli N, Alimena G, Montanaro M, Palandri F.

Am J Hematol. 2016 Mar;91(3):318-21. doi: 10.1002/ajh.24269.

49.

Impact of exclusion criteria for the DASISION and ENESTnd trials in the front-line treatment of a 'real-life' patient population with chronic myeloid leukaemia.

Latagliata R, Carmosino I, Vozella F, Volpicelli P, De Angelis F, Loglisci MG, Salaroli A, De Luca ML, Montagna C, Serrao A, Molica M, Diverio D, Nanni M, Mancini M, Breccia M, Alimena G.

Hematol Oncol. 2017 Jun;35(2):232-236. doi: 10.1002/hon.2274. Epub 2015 Dec 9.

PMID:
26648184
50.

Dasatinib first-line: Multicentric Italian experience outside clinical trials.

Breccia M, Stagno F, Luciano L, Abruzzese E, Annunziata M, D'Adda M, Maggi A, Sgherza N, Russo-Rossi A, Pregno P, Castagnetti F, Iurlo A, Latagliata R, Cedrone M, Di Renzo N, Sorà F, Rege-Cambrin G, La Nasa G, Scortechini AR, Greco G, Franceschini L, Sica S, Bocchia M, Crugnola M, Orlandi E, Guarini A, Specchia G, Rosti G, Saglio G, Alimena G.

Leuk Res. 2016 Jan;40:24-9. doi: 10.1016/j.leukres.2015.11.008. Epub 2015 Nov 17.

PMID:
26643920

Supplemental Content

Loading ...
Support Center